A5014616578- Tuberculosis Research and Epidemiology
- Pneumocystis jirovecii pneumonia detection and treatment
- Mycobacterium research and diagnosis
- Bacterial Infections and Vaccines
- HIV/AIDS drug development and treatment
- Infectious Diseases and Tuberculosis
- Pneumonia and Respiratory Infections
- Diagnosis and treatment of tuberculosis
University of Washington
2011-2020
Public Health – Seattle & King County
2011-2020
The use of a rifamycin in anti-tuberculosis treatment regimens is crucial for shortening and achieving favorable outcomes. Rifampin (RMP) the recommended rifamycin, although adverse effects (AEs) may require its discontinuation. rifabutin (RFB), with activity against Mycobacterium tuberculosis, patients an RMP-related AE has not been well studied.To review our experience RFB tuberculosis (TB) treatment.We included TB who received their from 2003 to 2009. We evaluated indications and, if...
Abstract Background In the United States, tuberculosis (TB) incidence rates are highest among adults aged ≥65 years. We performed this study to evaluate outcomes of older patients undergoing treatment for TB disease, including frequency adverse events related treatment. Methods This evaluated adult who were diagnosed with pulmonary from 2009 2014 in King County, Washington. Patient characteristics, manifestation TB, and different age groups compared. Frequency type that resulted interruption...
Abstract Background US hematopoietic cell transplantation (HCT) recipients have a low prevalence of latent tuberculosis infection (LTBI), but if latently infected they are at risk for progression to active tuberculosis. At our center, all HCT underwent LTBI testing pretransplant by tuberculin skin (TST) until 2013 when we implemented targeted screening program. Our objective was assess the utility program that incorporated questionnaire target TST and QuantiFERON TB Gold (QFT) testing....